NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT06573723 2026-01-14Institutional Registry of Rare DiseasesHospital Italiano de Buenos AiresRecruiting380 enrolled